Major depressive disorder, a common debilitating illness, is one of the leading causes of disability and disease worldwide. Different drugs for the treatment of patients with major depression can be used. Vortioxetine...Major depressive disorder, a common debilitating illness, is one of the leading causes of disability and disease worldwide. Different drugs for the treatment of patients with major depression can be used. Vortioxetine for the treatment of major depressive disorder was approved by the Food and Drug Administration (FDA) in 2013. This study aimed to evaluation efficacy and safety Vortioxetine 20 mg/d compared placebo in major depressive disorder. To conduct this study, we searched Pub Med, Cochrane library, Scopus, and Central Register of Controlled Trials. This study by including randomized controlled trials (RCTs) that evaluated this study by including randomized controlled trials (RCTs) that evaluated Vortioxetine 20 mg/d in patients with major depressive disorder. Data analysis was conducted by standard mean different ratios (SMD) with 95% confidence intervals (CIs), P values and odds ratios (ORs) for adverse events with 95% confidence intervals (CIs) and P values;heterogeneity testing and sensitivity analysis was also performed in this study. We found that 4 articles met the inclusion criteria and were finally used for this meta-analysis. Results showed statistical significance in the MADRS (Montgomery-Åsberg Depression Rating Scale), SMD = -4.75 with 95% CI [-6.84, -2.65] and P value < 0.00001), for Clinical Global Impression Scale-Improvement (CGI-I) SMD was -4.34 with 95% CI [-6.41, -2.27] and P value < 0.00001, and for Sheehan Disability Scale (SDS) SMD was -2.62 with 95% CI [-3.99, -1.25] and P value < 0.00001. The pooled analysis for safety demonstrated for diarrhea OR = 0.92 with 95% CI [0.46, 1.83] , P value = 0.09, for dry mouth OR = 1.74 with 95% CI [1.07, 2.83] , P value = 0.80, for dizziness OR = 1.62 with 95% CI [0.72, 3.66] , P value = 0.05, for fatigue OR = 1.17 with 95% CI [0.34, 4.08], P value = 0.07, for headache OR = 1.28 with 95% CI [0.91, 1.79], P value = 0.60 and for nausea OR = 4.78 with 95% CI [3.43, 6.67], P value = 0.61. Vortioxetine 20 mg/d versus placebo showed a significant difference for nausea and dry mouth, but no significant differences were observed for the four adverse effects. In several studies of the drug Vortioxetine 20 mg/d, the treatment of major depressive illness has been more effective for evaluating the effectiveness of this drug, which must be more clinical studies of sound.展开更多
Background: Major depressive disorder is a serious public health problem affecting the lives of millions in the worldwide and leading causes of disability and disease. This study aimed to evaluate the efficacy and saf...Background: Major depressive disorder is a serious public health problem affecting the lives of millions in the worldwide and leading causes of disability and disease. This study aimed to evaluate the efficacy and safety of Vortioxetine and Duloxetine 60 mg compared to placebo for the treatment of major depressive disorder. Method: We searched the Cochrane library, Pub Med, CRD, Scopus, and Central Register of Controlled Trials to January 2015. We also searched ClinicalTrials.gov, International depressive disorder Conference and the Anxiety Disorders and Depression Conference. We identified that five randomized clinical trials were ultimately included in a Meta analysis. Data analysis was conducted by Standardized Mean Differences (SMD) for Montgomery-Åsberg Depression Rating Scale (MADRS), and Odds Ratio (OR) for adverse events. The SMD and OR reported by 95% CI. Results: Results showed statistical significance in the MADRS for Vortioxetine (SMD = ﹣3.29;95% CI ﹣4.47 to ﹣2.10;I2 = 99.3%) and for Duloxetine 60 mg (SMD = ﹣6.35;95% CI ﹣8.84, ﹣3.87;I2 = 99.3%). Results showed that the Vortioxetine 2.5, 5, 10, 15, 20 mg and overall compared to placebo showed a significance for Nausea and no significance for diarrhea, dry mouth, dizziness, fatigue and headache. Also results of Duloxetine 60 mg showed a significant effect for dry mouth, dizziness, fatigue and nausea. Conclusion: It is necessary to do more studies so as to better assess and much more powerful than the evidence for the use of this drug in the treatment of depression.展开更多
Background:Street children are forced to spend a lot of time away from their homes and some of them do not have homes at all,due to economic and family problems,which makes them exposed to many health problems,such as...Background:Street children are forced to spend a lot of time away from their homes and some of them do not have homes at all,due to economic and family problems,which makes them exposed to many health problems,such as the hepatitis C virus(HCV)infection.Iran,like many other countries in the world,experiences the burden of street children,however,the rate of HCV among street children is virtually unknown.This study aimed to determine the prevalence of HCV among street children in Iran.Main body:This systematic review and meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.The study protocol of this review was registered in PROSPERO under identification term CRD42018082336.A comprehensive literature search was conducted to identify published studies reporting on the prevalence of HCV among street children in Iran.Several international scholarly databases,including Web of Science,PubMed^(■)/MEDLINE^(■),Embase,Scopus®,Google Scholar and Directory of Open Access Journals,as well as Iranian databases such as MagIran and Barakathns were searched.Studies published between 1988 and December 2017 with any of the following keywords were selected:(street OR homeless OR labour)AND(children OR child OR infant)AND(hepatitis C OR hepatitis C virus OR HCV OR viral hepatitis OR hepatitis OR hepacivirus)AND Iran.Moreover,a grey literature search was performed in order to obtain other potentially relevant studies.The search was carried out without any language restrictions.Four studies,surveying a total of 1691 street children,conducted between 2006 and 2017 were found to be eligible for inclusion in the review and therefore analysed.Three studies were conducted in Tehran and one in Isfahan.The prevalence of HCV among street children in Iran was found to be high,at 2.4%(95%CI:1.8-3.3).Conclusions:Since the prevalence of HCV among street children in Iran is quite high,health decision-and policy-makers should pay more attention to street children and widen support channels,both social and economic.Further studies should be conducted among street children in different cities of Iran to add to the knowledge base of HCV among street children in the country.The health system should provide facilities for street children to be screened to quickly diagnose illnesses and prevent them from developing complications.展开更多
文摘Major depressive disorder, a common debilitating illness, is one of the leading causes of disability and disease worldwide. Different drugs for the treatment of patients with major depression can be used. Vortioxetine for the treatment of major depressive disorder was approved by the Food and Drug Administration (FDA) in 2013. This study aimed to evaluation efficacy and safety Vortioxetine 20 mg/d compared placebo in major depressive disorder. To conduct this study, we searched Pub Med, Cochrane library, Scopus, and Central Register of Controlled Trials. This study by including randomized controlled trials (RCTs) that evaluated this study by including randomized controlled trials (RCTs) that evaluated Vortioxetine 20 mg/d in patients with major depressive disorder. Data analysis was conducted by standard mean different ratios (SMD) with 95% confidence intervals (CIs), P values and odds ratios (ORs) for adverse events with 95% confidence intervals (CIs) and P values;heterogeneity testing and sensitivity analysis was also performed in this study. We found that 4 articles met the inclusion criteria and were finally used for this meta-analysis. Results showed statistical significance in the MADRS (Montgomery-Åsberg Depression Rating Scale), SMD = -4.75 with 95% CI [-6.84, -2.65] and P value < 0.00001), for Clinical Global Impression Scale-Improvement (CGI-I) SMD was -4.34 with 95% CI [-6.41, -2.27] and P value < 0.00001, and for Sheehan Disability Scale (SDS) SMD was -2.62 with 95% CI [-3.99, -1.25] and P value < 0.00001. The pooled analysis for safety demonstrated for diarrhea OR = 0.92 with 95% CI [0.46, 1.83] , P value = 0.09, for dry mouth OR = 1.74 with 95% CI [1.07, 2.83] , P value = 0.80, for dizziness OR = 1.62 with 95% CI [0.72, 3.66] , P value = 0.05, for fatigue OR = 1.17 with 95% CI [0.34, 4.08], P value = 0.07, for headache OR = 1.28 with 95% CI [0.91, 1.79], P value = 0.60 and for nausea OR = 4.78 with 95% CI [3.43, 6.67], P value = 0.61. Vortioxetine 20 mg/d versus placebo showed a significant difference for nausea and dry mouth, but no significant differences were observed for the four adverse effects. In several studies of the drug Vortioxetine 20 mg/d, the treatment of major depressive illness has been more effective for evaluating the effectiveness of this drug, which must be more clinical studies of sound.
文摘Background: Major depressive disorder is a serious public health problem affecting the lives of millions in the worldwide and leading causes of disability and disease. This study aimed to evaluate the efficacy and safety of Vortioxetine and Duloxetine 60 mg compared to placebo for the treatment of major depressive disorder. Method: We searched the Cochrane library, Pub Med, CRD, Scopus, and Central Register of Controlled Trials to January 2015. We also searched ClinicalTrials.gov, International depressive disorder Conference and the Anxiety Disorders and Depression Conference. We identified that five randomized clinical trials were ultimately included in a Meta analysis. Data analysis was conducted by Standardized Mean Differences (SMD) for Montgomery-Åsberg Depression Rating Scale (MADRS), and Odds Ratio (OR) for adverse events. The SMD and OR reported by 95% CI. Results: Results showed statistical significance in the MADRS for Vortioxetine (SMD = ﹣3.29;95% CI ﹣4.47 to ﹣2.10;I2 = 99.3%) and for Duloxetine 60 mg (SMD = ﹣6.35;95% CI ﹣8.84, ﹣3.87;I2 = 99.3%). Results showed that the Vortioxetine 2.5, 5, 10, 15, 20 mg and overall compared to placebo showed a significance for Nausea and no significance for diarrhea, dry mouth, dizziness, fatigue and headache. Also results of Duloxetine 60 mg showed a significant effect for dry mouth, dizziness, fatigue and nausea. Conclusion: It is necessary to do more studies so as to better assess and much more powerful than the evidence for the use of this drug in the treatment of depression.
基金This study was part of a PhD thesis supported by the School of Health Management,Iran University of Medical Sciences(ID:IUMS/SHMIS_1396/9423557001).
文摘Background:Street children are forced to spend a lot of time away from their homes and some of them do not have homes at all,due to economic and family problems,which makes them exposed to many health problems,such as the hepatitis C virus(HCV)infection.Iran,like many other countries in the world,experiences the burden of street children,however,the rate of HCV among street children is virtually unknown.This study aimed to determine the prevalence of HCV among street children in Iran.Main body:This systematic review and meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.The study protocol of this review was registered in PROSPERO under identification term CRD42018082336.A comprehensive literature search was conducted to identify published studies reporting on the prevalence of HCV among street children in Iran.Several international scholarly databases,including Web of Science,PubMed^(■)/MEDLINE^(■),Embase,Scopus®,Google Scholar and Directory of Open Access Journals,as well as Iranian databases such as MagIran and Barakathns were searched.Studies published between 1988 and December 2017 with any of the following keywords were selected:(street OR homeless OR labour)AND(children OR child OR infant)AND(hepatitis C OR hepatitis C virus OR HCV OR viral hepatitis OR hepatitis OR hepacivirus)AND Iran.Moreover,a grey literature search was performed in order to obtain other potentially relevant studies.The search was carried out without any language restrictions.Four studies,surveying a total of 1691 street children,conducted between 2006 and 2017 were found to be eligible for inclusion in the review and therefore analysed.Three studies were conducted in Tehran and one in Isfahan.The prevalence of HCV among street children in Iran was found to be high,at 2.4%(95%CI:1.8-3.3).Conclusions:Since the prevalence of HCV among street children in Iran is quite high,health decision-and policy-makers should pay more attention to street children and widen support channels,both social and economic.Further studies should be conducted among street children in different cities of Iran to add to the knowledge base of HCV among street children in the country.The health system should provide facilities for street children to be screened to quickly diagnose illnesses and prevent them from developing complications.
